89 Recent strides in melanoma research are transforming patient outcomes by targeting the genetic and molecular traits that drive this aggressive skin cancer. Melanoma, responsible for 331,722 new cases and 58,667 deaths worldwide, is particularly challenging to treat due to its tendency to resist conventional therapies. However, breakthroughs in understanding key mutations have led to promising advances in targeted therapies and immunotherapy. The findings were published in the journal Biomedicines. Significant research focuses on the role of mutations in genes like BRAF, NRAS, and KIT, which fuel tumour growth by triggering dysregulated molecular pathways. Specifically, these genes activate pathways such as MAPK and PI3K/Akt/mTOR, promoting rapid tumour progression and complicating treatment. Recent drugs like BRAF inhibitors, including vemurafenib, selectively target mutated BRAF proteins, delivering significant results for patients with BRAF mutations. The use of combined therapies—targeting both BRAF and MEK pathways—has proven especially effective, increasing survival rates for patients who would otherwise face poor outcomes. Understanding the tumour microenvironment has also revolutionised treatment approaches. This microenvironment, composed of immune cells and signalling molecules surrounding the tumour, can either hinder or promote tumour resistance to treatments. Immunotherapy, particularly immune checkpoint inhibitors like pembrolizumab, has emerged as a game-changer, strengthening the immune system’s ability to target melanoma cells. These inhibitors work by blocking the tumour’s mechanisms that prevent immune cell recognition, which has shown lasting responses for many patients. Another promising development lies in personalised mRNA vaccines. These vaccines are designed to stimulate the immune system by presenting tumour-specific antigens, making the body more effective at identifying and attacking melanoma cells. Combining these vaccines with immune checkpoint inhibitors is now under investigation, with initial trials showing potential for improving immune response and patient outcomes. Despite these advances, challenges remain. Melanoma’s resilience often leads to resistance to treatments over time, particularly in advanced stages. However, ongoing research into molecular mechanisms and the tumour microenvironment continues to provide hope. As scientists refine targeted therapies, personalised treatment options are expanding, aiming to offer more sustainable and effective solutions for patients worldwide.